Featured Research

from universities, journals, and other organizations

Cost-effectiveness research needs to be considered in developing new medical technology, expert argues

Date:
February 18, 2011
Source:
University of Chicago
Summary:
Cost-effectiveness analysis should play a bigger role in the health care system, argues a medical research expert. "The effects of science and technology on health care costs depend on the policy context in which those technologies are developed and applied," said David Meltzer in a recent presentation.

Cost-effectiveness analysis should play a bigger role in the American health care system, argued a University of Chicago researcher Feb. 18 at the annual conference of the American Association for the Advancement of Science.

"The effects of science and technology on health care costs depend on the policy context in which those technologies are developed and applied," said David Meltzer, Associate Professor of Medicine, in his presentation, "Policies to Mobile Technology and Science for Health Care Cost Control."

Meltzer, who also holds a PhD in economics, pointed out that insurance reimbursement policies are especially important in determining which health technologies are developed and how they are used. Currently, national policymakers resist using cost-effectiveness methods, in regards to health care and reimbursement, to determine which technologies are developed, he said.

As a result, health care costs are rising as expensive technology and unnecessary tests drive up expenses, he pointed out. Since 1960, health care spending has grown 2.5 percent more per year than the rest of the economy, he added.

"Much of the growth comes from the quantity of medical procedures," he said.

For example, some cholesterol tests for older men and exercise tests for middle-aged men have not been shown to be cost-effective, he pointed out.

Additionally, pap smear tests, which women usually undergo annually to detect cervical cancer, could be done nearly as effectively every three years at a great savings.

Research shows that the impact of using pap smear tests every three years increases life expectancy by 70 days at a cost of $500. The same test given annually at a total cost of $1,500 increases life expectancy by 71 days, he pointed out. Under current medical standards, 63 percent of women receive pap smear tests annually, while 18 percent receive them every three years.

"Because technology is the major driver of increases in health care and a critical driver of improvements in health, rigorous methods to assess the costs and effectiveness of health care technology are critical for effective resource allocation," Meltzer said. By using cost-effectiveness methods in studying health care, researchers and policymakers can better understand the value of innovation, he said.

"Cost-effectiveness methods have the potential to address policy questions other than reimbursement policy that can help mobilize technology and science to control health care costs while maximizing health outcomes," he said.

In addition to being an a faculty member in the Department of Medicine at the University of Chicago, Meltzer is an associated faculty member in the University's Harris School of Public Policy Studies and its Department of Economics. He is director of the University's Center for Health and the Social Sciences. The center, founded in 2005, promotes interdisciplinary health research and training initiatives across campus.


Story Source:

The above story is based on materials provided by University of Chicago. Note: Materials may be edited for content and length.


Cite This Page:

University of Chicago. "Cost-effectiveness research needs to be considered in developing new medical technology, expert argues." ScienceDaily. ScienceDaily, 18 February 2011. <www.sciencedaily.com/releases/2011/02/110218142448.htm>.
University of Chicago. (2011, February 18). Cost-effectiveness research needs to be considered in developing new medical technology, expert argues. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/02/110218142448.htm
University of Chicago. "Cost-effectiveness research needs to be considered in developing new medical technology, expert argues." ScienceDaily. www.sciencedaily.com/releases/2011/02/110218142448.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins